Literature DB >> 27722793

Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease.

Julie Obert1, Olivia Freynet1, Hilario Nunes1,2, Pierre-Yves Brillet3, Makoto Miyara4,5, Robin Dhote6, Dominique Valeyre1,2, Jean-Marc Naccache7,8.   

Abstract

Interstitial lung disease (ILD) is a common form of extramuscular involvement in patients with polymyositis/dermatomyositis and is associated with poor prognosis. This study was designed to describe the long-term outcome of myositis-associated ILD. This retrospective observational study was conducted in 48 consecutive patients. Two groups defined according to outcome were compared to determine prognostic factors: a "severe" group (vital capacity [VC] < 50 % or carbon monoxide transfer factor [TLCO] < 35 % or death or lung transplantation) and a "nonsevere" group (other patients). The study population comprised 31 women and 17 men with a median age of 49.5 ± 13.6 years. Mean PFT results at the onset of ILD were 56.9 ± 23.1 % pred. for VC and 42.1 ± 16.6 % pred. for TLCO. Median (range) follow-up was 65 (2-204) months. Three patients (6.4 %) died. At last follow-up, 19 patients were classified in the "severe" group and 27 patients were classified in the "nonsevere" group. Two patients lost to follow-up after less than 12 months were excluded from this analysis. Multivariate analysis identified two independent prognostic factors: VC at onset of ILD [OR 0.95 (95 % CI 0.90-0.99)] and myopathic changes on electromyography [OR 5.76 (95 % CI 1.10-30.3)]. Patients treated in our pulmonology department for myositis-associated ILD had severe initial PFT results but a low mortality rate. Independent prognostic factors at presentation were initial VC and myopathic changes on electromyography. This study highlights the need for studies focusing on the correlation between muscle and lung pathogenic mechanisms.

Entities:  

Keywords:  Dermatomyositis; Interstitial lung disease; Myositis; Polymyositis; Prognosis

Mesh:

Year:  2016        PMID: 27722793     DOI: 10.1007/s00296-016-3571-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen
Journal:  Autoimmun Rev       Date:  2012-02-03       Impact factor: 9.754

3.  Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.

Authors:  Yves Troyanov; Ira N Targoff; Jean-Luc Tremblay; Jean-Richard Goulet; Yves Raymond; Jean-Luc Senécal
Journal:  Medicine (Baltimore)       Date:  2005-07       Impact factor: 1.889

Review 4.  Pulmonary disease in polymyositis/dermatomyositis.

Authors:  B F Dickey; A R Myers
Journal:  Semin Arthritis Rheum       Date:  1984-08       Impact factor: 5.532

Review 5.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

Review 6.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival.

Authors:  Baptiste Hervier; Alain Meyer; Céline Dieval; Yurdagul Uzunhan; Hervé Devilliers; David Launay; Matthieu Canuet; Laurent Têtu; Christian Agard; Jean Sibilia; Mohamed Hamidou; Zahir Amoura; Hilario Nunes; Olivier Benveniste; Philippe Grenier; David Montani; Eric Hachulla
Journal:  Eur Respir J       Date:  2013-02-08       Impact factor: 16.671

9.  Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.

Authors:  I Tillie-Leblond; M Wislez; D Valeyre; B Crestani; A Rabbat; D Israel-Biet; M Humbert; L J Couderc; B Wallaert; J Cadranel
Journal:  Thorax       Date:  2007-06-08       Impact factor: 9.139

10.  A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.

Authors:  Isabel C Mira-Avendano; Joseph G Parambil; Ruchi Yadav; Valeria Arrossi; Meng Xu; Jeffrey T Chapman; Daniel A Culver
Journal:  Respir Med       Date:  2013-03-19       Impact factor: 3.415

View more
  3 in total

Review 1.  Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.

Authors:  Christopher A Mecoli; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 2.  Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment.

Authors:  Baptiste Hervier; Yurdagül Uzunhan
Journal:  Front Med (Lausanne)       Date:  2020-01-17

3.  Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.

Authors:  Zhiqian Bai; Guifen Shen; Lingli Dong
Journal:  Int J Rheum Dis       Date:  2021-05-24       Impact factor: 2.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.